Biotech is Health
EuropaBio’s DNA
5 Key Recommendations

1. **Foster innovation-enabling regulation**
   
a. Improve EU guidance documents to develop better clinical data for patients suffering from rare conditions and expand global regulatory cooperation through mutual recognition of good manufacturing practice, batch testing and good clinical practice

b. Support innovation and patient access by advocating new payment models based on the value that new treatments bring to society and healthcare systems

c. Optimise the EU ecosystem for cell and gene therapies through regulatory adaptable pathways, efficient early scientific advice and better collection of clinical data for patients, in particular in the area of rare conditions

2. **Build trust**
   
a. Involve patients in the entire cycle of medicines development and associated evidence generation to achieve patient-centred and outcome-based healthcare

b. Engage in an inclusive ethical discussion on the potential of human gene editing to advocate responsible research towards new treatments

c. Deliver a European harmonised health data network via a consistent digital health strategy. Leverage real-world data and patient registries to support new value assessment models with the inclusion of European Reference Networks
3 | Protect intellectual property

a. Advocate for an internationally competitive suite of incentives and R&D reward mechanisms to ensure continued investment in bio-pharmaceutical innovation, such as in rare disease medicines and advanced therapies

b. Ensure the predictability and certainty of the European pharmaceutical incentives framework that creates the conditions for increased investment in R&D in the EU

c. Strive to enhance the competitiveness of the EU IP system, further incentivising medicines development in areas of high unmet needs

4 | Establish a supportive and fit-for-healthcare funding framework

a. Foster a strong EU research and innovation framework to support discovery bioscience and its translation into medicines, including in the context of Horizon Europe Cancer mission, the Innovative Health Initiative and the European Joint Programme for Rare Diseases

b. Secure easy access to attractive funding for SMEs and start-ups towards a strong health biotech cluster and eco-system in its early phase

c. Work towards the establishment of a more unified and better capitalised market for life sciences R&D
Develop a strategy for biotechnology-focused industrial innovation

a. Achieve a world-class EU biopharma ecosystem by benchmarking EU performance and elaborating an EU Life Sciences and Biotechnology Strategy built on cutting-edge and breakthrough innovation.

b. Build on current healthcare biotechnology strength to improve transfer from research to new healthcare solutions and work on the combination of digitisation, big data and AI with biotech to generate high added value manufacturing processes and healthcare services which benefit society, the environment and the economy.

c. Promote partnerships between academia and biopharmaceutical companies to address skill and research gaps to foster strong EU knowledge-based bioindustries.
HEALTHCARE COMPANIES AND CONSULTANCIES:

- **22 x** small-sized
- **7 x** medium-sized
- **14 x** large-sized

EuropaBio healthcare members spend **€70 Billion a year on R&D = 17.8% revenue**

EuropaBio SMEs invest close to **437% of revenue in R&D**

> > 900,000 employees worldwide, > 300,000 in Europe

A new treatment of cancer or a rare disease is **72% likely to come from an emerging biopharma company.**

Over 1050 medicines developed by EuropaBio’s members, with over 728 in development

> **160 drugs** for rare diseases approved in the EU

> > 3.4 million Europeans are diagnosed with cancer every year and 30 million Europeans suffer from rare diseases

November 2019
“This is an inspiring time for healthcare biotech with many new transformative therapies on the horizon for patients. Creating the right life science and biotechnology ecosystem in Europe is even more critical to benefit from the full potential of healthcare innovations.”

JOANNA DUPONT-INGLIS,
SECRETARY GENERAL,
EUROPABIO